RE: Evidence building on Reolysin's effectiveness1999
To date the ONC Glioblastoma trial using Reolysin has enrolled terminally sick patients, who were diagnosed with the nastiest forms of brain cancer and were only expected to live a few weeks. Treatment with Reolysin has effectively treated these cancer patients and has extended their lives to 11 months and counting, giving these patients the increased prospect of enhanced survivablility.
seeing as you used the expresseion, "to date", what is/are your source(s) to confirm how many patients have been treated and how many are still with us as of today, or are you simply reporting old news as new?
Also contributing to the "real deal" are preliminary results from the prostate trial which demonatrated that approximately 66% of the prostate patients treated with Reolysin have had effective results from the treatment
i would hope the results were better than 2/3, since as i understand the prostate trials, all 6 of the patients treated "to date" have had their prostate gland (including the localized cancerous tumour) removed. According to onc, that is part of standard treatment for this type of cancer, and in and of itself has a success rate much higher than 2/3.
this trial had much more to do with reviewing the histopathopathological efficacy of reolysin on glands that were removed from patients as part of their standard treatment.
The way you put it, your target audience might deduce, our doubledeuce in your case
that reolysin actually reduced the effectiveness of the standard treatment for localized T2 prostate cancer.
wouldn't want that now, would we?